Part 7/12:
A groundbreaking cancer drug named D starlab has reportedly achieved a 100% cure rate during clinical trials, specifically targeting rectal cancer. The FDA has granted breakthrough therapy designation, ensuring this monoclonal antibody’s expedited development and approval process. If successful in further testing, this innovative treatment could redefine cancer care, sparing patients from the hardships of traditional therapies.